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Abstract
Background: Cisplatin is more often used to treat ovarian cancer (OvCa), which provides modest survival advantage 
primarily due to chemo-resistance and up regulated anti-apoptotic machineries in OvCa cells. Therefore, targeting the 
mechanisms responsible for cisplatin resistance in OvCa cell may improve therapeutic outcomes. We have shown that 
ovarian cancer cells express CC chemokine receptor-9 (CCR9). Others have also shown that CCL25, the only natural 
ligand for CCR9, up regulates anti-apoptotic proteins in immature T lymphocytes. Hence, it is plausible that CCR9-
mediated cell signals might be involved in OvCa cell survival and inhibition of cisplatin-induced apoptosis. In this study, 
we investigated the potential role and molecular mechanisms of CCR9-mediated inhibition of cisplatin-induced 
apoptosis in OvCa cells.
Methods: Cell proliferation, vibrant apoptosis, and TUNEL assays were performed with or without cisplatin treatment 
in presence or absence of CCL25 to determine the role of the CCR9-CCL25 axis in cisplatin resistance. In situ Fast 
Activated cell-based ELISA (FACE) assays were performed to determine anti-apoptotic signaling molecules responsible 
for CCL25-CCR9 mediated survival.
Results: Our results show interactions between CCR9 and CCL25 increased anti-apoptotic signaling cascades in OvCa 
cells, which rescued cells from cisplatin-induced cell death. Specifically, CCL25-CCR9 interactions mediated Akt, 
activation as well as GSK-3β and FKHR phosphorylation in a PI3K-dependent and FAK-independent fashion.
Conclusions: Our results suggest the CCR9-CCL25 axis plays an important role in reducing cisplatin-induced apoptosis 
of OvCa cells.
Background
OvCa is the most lethal among gynaecologic malignan-
cies [1]. Cancer cells develop resistance to chemotherapy
by inactivating apoptotic factors and enhancing survival
pathways that antagonize apoptotic signals [2]. The first-
line chemotherapeutic agent for OvCa is cisplatin. Unfor-
tunately, many ovarian tumors show resistance to cispla-
tin, characterized by decreased susceptibility to
apoptosis. Intracellular signalling by chemokine recep-
tors primarily involves Gαi, along with the Gβ-Gγ dimer
of the heterotrimeric G proteins [3], which activate the
PI3K/Akt pathway. Downstream mediators of PI3K
d i r e c t l y  i n d u c e  A k t  a c t i v a t i o n  [ 4 ] .  P h o s p h o ry l a t e d  A k t
promotes cell survival by inactivating pro-apoptotic fac-
tors, such as forkhead transcriptional factor (FKHR) and
glycogen synthase kinase-3β (GSK-3β) [5]. Hence, this
anti-apoptotic-survival pathway has been shown to play a
significant role in cisplatin resistance [6].
CCR9 signalling has been shown to facilitate immature
T cell survival through PI3K and Gαi protein-dependent
activation of Akt [7]. Alternatively, chemokine receptors
aggregate with associated integrins on lipid rafts follow-
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ing stimulation to promote FAK phosphorylation, which
could presumably support anti-apoptotic mechanisms via
FAK-Akt signaling. This study investigates the role of
CCR9 signalling on OvCa cell survival and cisplatin resis-
tance. We show for the first time that CCL25-CCR9
interactions in OvCa cells provide protection against cis-
p l a t i n - i n d u c e d  c e l l  d e a t h .  W e  a l s o  r e p o r t  t h a t  C C L 2 5
promotes proliferation and CCR9-dependent anti-apop-
totic signalling via the PI3K/Akt/GSK/FKHR pathway
and independent of FAK. These studies suggest expres-
sion of functional CCR9 contributes to ovarian tumor cell
survival.
Methods
Cell Lines and cell culture
Human OvCa cell line, OVCAR-3, was obtained from the
ATCC. The cells were cultured in RPMI 1640 (Mediatech,
Inc.) at 37°C and 5% CO2 with 10% fetal bovine serum
(FBS; Sigma). The SKOV-3 cell line was obtained from
Dr. Negrin [8]. SKOV-3 cells were cultured in Ham's
F12K medium with 2 mM L-glutamine and adjusted to
contain 1.5 g/L sodium bicarbonate (ATCC) with 10%
FBS at 37°C with 5% CO2. After five passages in Ham's
F12K media, SKOV-3 cells were switched to RPMI-1640
with 10% FBS. Prior to each experiment, cells were cul-
tured for 24 hours in RPMI 1640 and 2% charcoal-striped
FBS.
Cell Proliferation Assay
OvCa cells (105) were cultured alone or with 100 ng/ml
CCL25 + 1 μg/ml of isotype control antibody or 100 ng/
ml CCL25 + 1 μg/ml anti-CCR9 antibody (clone 112509,
R&D Systems) for 24 hours with 0, 0.5, 5, 10, 25 and 50
μg/ml of cisplatin. Incorporation of bromodeoxyuridine
(BrdU) into newly synthesized DNA permits indirect
detection of rapidly proliferating cells. Hence, this assay
was used according to manufacturer's instructions to
estimate OvCa cell growth. Briefly, cells were treated with
BrdU for 18 hours at 37°C. Media containing labelling
solution was removed and cells were washed twice with
media containing 10% serum. OvCa cells were fixed with
200 μl of fixative solution for 30 minutes at ~25°C and
washed as before. Next, cells were incubated with 100 μl
of nuclease solution for 30 minutes at 37°C and washed 3
times. Subsequently, 100 μl of anti-BrdU antibody was
added, incubated for 30 minutes at 37°C, and washed 3
times. BrdU incorporation by OvCa cells was detected by
peroxidase substrate reaction. After the extinction of this
reaction, the samples were measured in a micro plate
reader at 405 nm with a reference wavelength at approxi-
mately 490 nm.
Vybrant Apoptosis Assay
OvCa cells were cultured with 0 or 5 μg/ml of cisplatin,
along with no additions or 100 ng/ml of CCL25 plus 1 μg/
ml of anti-CCR9 or isotype control antibodies for 24
hours. The cells were harvested and washed in cold PBS
and the cell density was adjusted to 106 cells/ml. Subse-
quently, cells were stained with Annexin V and Propid-
ium Iodide (PI) using the Vybrant #3 assay (Invitrogen),
according to manufacturer's instructions. The stained
cells were analyzed by flow cytometry using UV/488 nm
dual excitation and the fluorescence emission was mea-
sured at 530 nm and 575 nm.
Terminal Transferase dUTP Nick End Labeling (TUNEL) 
Assay
OvCa cells were cultured with 0 or 5 μg/ml of cisplatin,
along with no additions or 100 ng/ml of CCL25 plus 1 μg/
ml of anti-CCR9 or isotype control antibodies for 24
hours. Apoptosis was measured by TUNEL assay (Milli-
pore) according to the manufacturer's instructions.
Briefly, following treatment the cells were fixed with 4%
paraformaldehyde in 0.1 M NaH2PO4, 7.4 pH for 15 min-
utes. After washing in PBS three times, the cells were
incubated with 0.05% Tween-20 in PBS for 15 minutes.
After washing in PBS, the cells were incubated with TdT
end-labelling cocktail for 60 minutes. Termination buffer
was added to stop the reaction. After washing 4 times in
PBS, cells were blocked for 20 minutes and stained with
avidin-fluorescein isothiocyanate (FITC) solution for 30
minutes. After washing with PBS 3 times, fluorescence
plate reader quantified the fluorescence of TUNEL posi-
tive cells.
Fast Activated cell-based ELISA (FACE) assay
The level of total and phosphorylated PI3Kp85-Tyr, Akt-
Ser473, GSK-3β-Ser9, and FKHR-Thr24 were quantified
using Fast Activated Cell-based ELISA (FACE) assays
(Active Motif) according to the manufacturer's protocol.
Briefly , OvCa cells were cultured in 96-well plates (5 ×
103 cells/well) 200 μl of culture medium (in triplicate for
each treatment) one day prior to manipulation. OvCa
cells were treated with 0 or 5 μg/ml of cisplatin, along
with no additions or 100 ng/ml of CCL25 plus 1 μg/ml of
anti-CCR9 or isotype control antibodies for 24 hours. In
addition, cells were treated with or without kinase inhibi-
tors of PI3K (wortmannin, Sigma), and FAK (PF-573, 228,
Pfizer). Cells were then fixed with 4% formaldehyde at
room temperature for 20 minutes, followed by washing
with PBS containing 0.1% Triton X-100. Endogenous per-
oxidase activity was quenched using 1% H2O2 in wash
buffer. The cells were incubated in antibody blocking buf-
fer, followed by incubations with phospho- or total anti-
PI3Kp85-, or Akt- or GSK-3β, -FKHR-specific primary
antibodies. After washing steps, horse raddish peroxidase
(HRP)-conjugated antibody was added and cells were
incubated for one hour at ~25°C. Subsequently, the plates
were developed and chemiluminescence was measured
using a Spectramax-2 plate reader (Molecular Devices).Johnson et al. Journal of Ovarian Research 2010, 3:15
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Finally, plates were washed and the number of cells in
each well was estimated by crystal violet staining, mea-
suring absorbance at 595 nm. Relative cell numbers were
then used to normalize chemiluminescent readings, and
the change in phosphorylation status was calculated by
dividing chemiluminscence detected using phospho pro-
tein-specific antibody with that of the total protein-spe-
cific antibody.
Statistics
The data were compared using a two-tailed Student's t
test and expressed as the mean ± SE. The results were
analyzed using the Stat view II program (Abacus Con-
cepts, Inc.) and were labelled statistically significant if p
values were < 0.01.
Results
Effects of CCL25 on cisplatin-induced growth inhibition
SKOV-3 cells incorporated BrdU at a higher rate than
OVCAR-3 cells (0.375 versus  0.250 OD405 nm, respec-
tively), which suggested SKOV-3 cells proliferated at a
higher rate compared to OVCAR-3 cells (Figure 1). In the
absence of cisplatin, CCL25 significantly enhanced BrdU
incorporation (i.e., growth) of OVCAR-3 and SKOV-3
cell lines by ~ 1.5-fold in comparison to untreated cells.
However, when these cells were treated with increasing
concentrations of cisplatin, CCL25 protected human
OvCa cells from cisplatin-mediated growth inhibition.
CCL25 optimally protected against 5 μg/ml or less cispla-
tin with 3.5 and 2.2-fold increases in OVCAR-3 and
SKOV-3 cell BrdU incorporation respectively, in compar-
ison to the untreated cells or CCL25 plus anti-CCR9 anti-
body treated cultures. In general, CCL25 treatment
abrogated the growth inhibition of OVCAR-3 and SKOV-
3 cell lines caused by cisplatin in a CCR9-dependent fash-
ion.
CCL25-induced cisplatin resistance of OvCa cell lines
Treatment of OVCAR-3 and SKOV-3 cell lines with cispl-
atin alone resulted in 96% and 95% respective increases in
apoptosis relative to the untreated cells (Figure 2). CCL25
treatment significantly lowered the percentage of apop-
totic OVCAR-3 and SKOV-3 cells. However, when the
OvCa cell lines were treated with anti-CCR9 antibody or
CCL25 + anti-CCR9 antibody, the percentage of apop-
totic cells was restored to levels of observed with cisplatin
treatment alone. Apoptosis was also assessed under the
same conditions by TUNEL assay. OvCa cell lines treated
with cisplatin alone resulted in ~130% increase in apop-
tosis relative to the untreated cells (Figure 3). The per-
centage of apoptotic cells was significantly lower than
controls when cells were treated with cisplatin and
CCL25. However, this CCL25-mediated survival was sig-
nificantly reduced by CCR9 blockade.
CCL25-CCR9 interactions impact on PI3Kp85-phospho Tyr 
and Akt-Ser473 activation
To determine the CCR9-mediated signals involved in
OvCa cell survival, we performed FACE assays for
PI3Kp85 phosphorylation (Figure 4). CCL25 induced a
significant increase in PI3Kp85 activation within 5 min-
utes. This increase was lower after 10 minutes, but was
still significantly higher than levels displayed by untreated
cells (i.e., 0 ng/ml of CCL25). As expected, the PI3K
inhibitor, wortmannin, reduced this increase. However,
CCL25-treated OvCa cells co-incubated with the FAK
inhibitor, PF-573, 228, continued to activate PI3Kp85.
When treated with cisplatin alone, there was no differ-
ence in PI3Kp85 activity in comparison to the untreated
cells. However, PI3Kp85 phosphorylation during cisplatin
treatment significantly increased 10 minutes post CCL25
co-incubation. Similarly, cisplatin treatment had no effect
on PI3Kp85 phosphorylation in the FAK-inhibited cells,
while the cisplatin and CCL25 combination induced an
immediate rise in PI3K activation, followed by a slight
Figure 1 CCL25 inhibits cisplatin-induced cell death. OVCAR-3 and 
SKOV-3 cells were cultured with 0 (circles) or 100 ng/ml of CCL25 plus 
isotype control (squares) or anti-CCR9 (triangles) antibodies for 24 
hours, along with increasing concentrations of cisplatin. Cell prolifera-
tion was determined by BrdU incorporation and assays were repeated 
3 times and performed in triplicate. Asterisk(s) (*) indicate statistical sig-
nificant differences (p < 0.01) between CCL25-treated and untreated 
OvCa cells.Johnson et al. Journal of Ovarian Research 2010, 3:15
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Figure 2 Percent change in the number of cisplatin-induced apoptotic OvCa cells. OVCAR-3 and SKOV-3 cells were cultured for 24 hours with 5 
μg/ml of cisplatin alone or with 0 or 100 ng/ml CCL25 plus 1 μg/ml of anti-human CCR9 or isotype and untreated cell were used as controls. Cells 
were harvested and stained with annexin V and propidium iodide. Dual flowcytometric analysis of Annexin V-FITC and propidium iodide (PI) staining. 
Living cell populations are clustered in the Q3 quadrant; cells in early apoptosis are in the Q4 quadrant; late apoptotic/necrotic cells are in the Q2 
quadrant.Johnson et al. Journal of Ovarian Research 2010, 3:15
http://www.ovarianresearch.com/content/3/1/15
Page 5 of 8
decrease. CCL25 also induced a gradual increase in Akt
phosphorylation 5 and 10 minutes after treatment. Wort-
mannin treatment abrogated this increase, but CCL25-
treated OvCa cells co-incubated with the FAK inhibitor
continued to activate Akt at significantly high levels. Cis-
platin treatment did not affect Akt phosphorylation, but
CCL25 plus cisplatin treatment caused significant
increases in Akt phosphorylation. While wortmannin
pretreatment inhibited this CCL25-mediated Akt activity,
cisplatin plus FAK inhibitor-treated and CCL25 co-incu-
bated cells had the same level of enhance Akt phosphory-
lation:total protein levels as OvCa cells treated with
CCL25 alone.
GSK-3β-Ser9 and FKHR-Thr24 phosphorylation following 
CCL25-CCR9 interactions
Akt inactivates GSK-3β and FKHR through phosphoryla-
tion. Hence, GSK-3β and FKHR FACE phosphorylation
assays were performed to determine the effect of CCL25
on these regulators of cell survival. CCL25 treatment sig-
nificantly increased phosphorylated:total GSK-3β protein
levels after 5 and 10 minutes treatments or combined
with cisplatin, compared to untreated cells (Figure 5).
Wortmannin treatment completely abolished CCL25-
mediated GSK-3β phosphorylation. Interestingly, PF-573,
228 plus CCL25 treatment had no effect on phosphoryla-
tion:total GSK-3β protein levels. Moreover, cisplatin
treatment had no effect on CCL25-mediated GSK-3β
phosphorylation, since CCL25 treatment of OvCa cells
co-incubated with cisplatin significantly increased phos-
phorylated:total GSK-3β protein levels after 5 and 10
minutes treatments. This activation was inhibited by
wortmannin treatment, but not by the FAK inhibitor.
CCL25 also significantly increased phosphorylated:total
FKHR levels after 5 and 10 minutes treatments, com-
pared to untreated cells. Wortmannin, but not PF-573,
228, treatment inhibited this increase. Neither cisplatin
treatment alone or in combination with the FAK inhibitor
affected FKHR phosphorylation following CCL25 treat-
ment. However, wortmannin treatment completely abro-
gated the CCL25-mediated increases in FKHR
phosphorylation in cisplatin-treated OvCa cells.
Discussion
A major cause of the high mortality rates due to OvCa is
chemotherapy resistance. Cisplatin is often the first drug
o f  c h o i c e  f o r  O v C a  t r e a t m e n t .  U n f o r t u n a t e l y ,  c i s p l a t i n
resistance is a major obstacle that impedes successful
chemotherapy and a major cause of treatment failure in
human OvCa. The balance between survival and apop-
totic signals determine a cell's sensitivity to chemother-
apy. Indeed, cancer cells develop resistance to
chemotherapy by means of inactivating apoptotic factors
and enhancing survival pathways that antagonize apopto-
sis signals [2]. However, the precise mechanisms of OvCa
cell cisplatin-sensitivity or survival are not known.
Chemokines function to direct leukocyte and cancer
cell migration, and play pivotal roles in cell survival [9].
Studies have demonstrated that CXCR4-CXCL12 inter-
actions promote the survival of tumor cells, allowing
growth under less favourable conditions. In particular,
CXCR4 mediates survival in glioma cells [10]. Recent
studies have also suggested that CCR9-CCL25 interac-
tions potentiate anti-apoptotic signalling to immature T
cells [11]. We have demonstrated that OvCa cells and tis-
sues express CCR9 and play important role in cell migra-
tion, invasion under the chemotactic gradient of CCL25
( u n p u b l i s h e d  o b s e r v a t i o n s ) .  H e r e  w e  s h o w  t h a t  C C R 9
also supports OvCa cell survival and cisplatin resistance.
For the first time, we show that CCL25 significantly
increases the proliferation of the OvCa cells in a CCR9-
dependent fashion. In the presence of cisplatin, CCL25
also supported OvCa cell survival. Even though higher
Figure 3 Percent change in the number of cisplatin-induced 
Tunel-positive OvCa cells. OVCAR-3 and SKOV-3 cells were cultured 
for 24 hours with 5 μg/ml cisplatin or with 0 or 100 ng/ml of CCL25 plus 
1 μg/ml of anti-human CCR9 or isotype control antibodies. Detection 
of apoptotic cells was carried out using the terminal deoxynucleotidyl 
transferase-mediated dUTP nick-end labelling (TUNEL) method. Apop-
totic cells exhibited nuclear green fluorescence with a standard fluo-
rescence filter set (520 ± 20 nm). Asterisks (*) indicate statistical 
significant differences (p < 0.01) between treated and untreated OvCa 
cells.Johnson et al. Journal of Ovarian Research 2010, 3:15
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doses of cisplatin abrogated this CCL25-mediated resis-
tance, our findings demonstrate that CCL25 confers sig-
nificant cisplatin resistance.
Studies have shown that CCR9 signalling plays a role in
immature T cell survival through PI3K and Gαi protein-
dependent activation of Akt/protein kinase B [11]. By
phosphorylation of its downstream effectors, Akt propa-
gates cell survival signalling that promotes cell prolifera-
tion, maintains cell growth and inhibits apoptosis. The
PI3K/Akt pathway has also been shown to be involved in
cisplatin resistance. Recent studies show that Akt inacti-
vation, through a PI3K inhibition, sensitizes OvCa cells to
cisplatin-induced cell death [6]. Phosphorylated Akt pro-
motes survival by phosphorylating and inactivating pro-
apoptotic factors, such as FKHR and GSK-3β [7]. FKHR is
a transcription factor that transactivates the expression of
death-activating proteins, such as Fas ligand (FasL) and
Bim [12]. Phosphorylation of FKHRL1 at Thr32, Ser253
and Ser315 prevents translocation of this protein to the
nucleus and loss of FKHR-mediated gene transcription
[13]. Recently, it was shown that activation of chemokine
receptors lead to phosphorylation of GSK-3β and FKHR
in a PI3K/Akt-dependent manner [14].
Taken together, our studies strongly support that
CCR9-CCL25 signalling enhances OvCa survival and cis-
platin resistance. Specifically, we show that CCL25
induces robust activation predominately through the
PI3K/Akt pathway and its downstream mediators, FKHR
and GSK-3β. Moreover, PI3K inhibition completely abro-
gated CCL25-mediated and CCR9-dependent cisplatin
resistance, Akt, GSK-3β, and FKHR phosphorylation.
Figure 4 PI3K and Akt activation after CCL25 treatment. Cells were tested for their ability to phosphorylate PI3Kp85-tyrosines and Akt-Ser473 fol-
lowing treatment with or without CCL25, cisplatin, wortmannin, and/or PF-573,228. FACE assays quantified in situ total and phosphorylated protein 
levels before (0) or after (5 or 10 minutes) CCL25 stimulation in the presence of cisplatin and inhibitors. The ratio of active (phosphorylated) to total 
PI3K or Akt are presented ± SEM from 3 separate experiments performed in triplicate. Asterisks (*) indicated statistical differences (p < 0.01) between 
untreated and treated cells.Johnson et al. Journal of Ovarian Research 2010, 3:15
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Chemokines-chemokine receptor interactions also sup-
port integrin clustering, which also increase FAK activa-
tion. FAK is a cytoplasmic protein tyrosine kinase
involved in the regulation of cell proliferation, migration,
and survival. FAK is constitutively associated with β-inte-
grins. Activated FAK has also been shown to support
PI3Kp85 phosphorylation following integrin clustering,
but the mechanism(s) is not fully understood [15]. FAK
inhibition did not effect CCL25-mediated PI3K, Akt,
FKHR, or GSK-3β phosphorylation in OvCa cells, which
suggest CCR9 signalling and survival mechanisms are
independent of FAK activity.
Conflicting studies demonstrated cisplatin activates
Akt in several cancer cell lines, which leads to cisplatin
resistance [16]. Moreover, it has been shown that cispla-
tin can transiently induce Akt-mediated phosphorylation
of FKHRL1 in the cisplatin-resistant cell line, CAOV-3,
with subsequent cytoplasmic retention of FKHRL1 and
cell survival [17]. However, cisplatin-treatment alone did
not lead to significant increases in phosphorylation of
PI3K, Akt, GSK-3β, or FKHR. In fact, cisplatin treatment
led to a slight down regulation of Akt activation. However
in the presence of CCL25 along with cisplatin, phospho-
rylation of Akt, GSK-3β and FKHR elevated to significant
levels. Taken together, these results suggest that CCL25
treatment contributes to OvCa survival and cisplatin
resistance. Moreover, we show that CCR9-dependent
anti-apoptotic signalling in OvCa cells involves the PI3K/
Akt cascade and phosphorylation of its downstream
mediators, GSK-3β and FKHR (Figure 6).
Figure 5 GSK-3β and FKHR phosphorylation following CCL25 treatment. Cells were tested for their ability to phosphorylate GSK-3β-Ser9 and 
FKHR-Thr24 following treatment with or without CCL25, cisplatin, wortmannin, and/or PF-573, 228. FACE assays quantified in situ total and phospho-
rylated protein levels before (0) or after (5 or 10 minutes) CCL25 stimulation in the presence of cisplatin and inhibitors. The ratio of phosphorylated:total 
GSK-3β or FKHR are presented ± SEM from 3 separate experiments performed in triplicate. Asterisks (*) indicated statistical differences (p < 0.01) be-
tween untreated and treated cells.Johnson et al. Journal of Ovarian Research 2010, 3:15
http://www.ovarianresearch.com/content/3/1/15
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Conclusions
Our results suggest that rapid activation of the PI3K/Akt
pathway occurs directly through the chemokine receptor/
G-proteins and independent of FAK activation. These
results support our hypothesis that CCL25-CCR9 inter-
action promotes OvCa survival and resistance to cispla-
tin.
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Figure 6 Inhibition of apoptotic signal in cisplatin resistant tu-
mor cells. More than one mechanism is usually observed in resistant 
cells, and this contributes to the multi-factorial nature of cisplatin resis-
tance. CCR9-dependent anti-apoptotic signalling in OvCa cells in-
volves the PI3K/Akt cascade and phosphorylation of its downstream 
mediators, GSK-3β and FKHR.